Last reviewed · How we verify
Inmazeb
Inmazeb, developed by ANRS, Emerging Infectious Diseases, is a marketed treatment for Ebola virus disease. The drug holds a key composition patent expiring in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of revenue data, which may indicate limited commercial success or market penetration.
At a glance
| Generic name | Inmazeb |
|---|---|
| Also known as | REGN-E3B, REGN-EB3 |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Target | Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Ebola virus disease
Common side effects
- Pyrexia
- Chills
- Tachycardia
- Tachypnea
- Vomiting
- Diarrhea
Serious adverse events
- Fever elevation requiring infusion discontinuation
Key clinical trials
- EBOla Post-Exposure Prophylaxis (PHASE3)
- Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers (PHASE2)
- R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |